Tannic acid as a natural antioxidant compound: Discovery of a potent metabolic enzyme inhibitor for a new therapeutic approach in diabetes and Alzheimer’s disease
Özet
Multiple studies have been recorded on the synthesis and design of multi‐aim
anti‐Alzheimer molecules. Using dual butyrylcholinesterase/acetylcholinesterase
inhibitor molecules has attracted more interest in the therapy for Alzheimer’s
disease. In this study, a tannic acid compound showed excellent inhibitory effects
against acetylcholine esterase (AChE), α‐glycosidase, α‐amylase, and butyrylcholinesterase
(BChE). IC50 values of tannic acid obtained 11.9 nM against
α‐glycosidase and 3.3 nM against α‐amylase, respectively. In contrast, Ki values
were found of 50.96 ± 2.18 μM against AChE and 53.17 ± 4.47 μM against
BChE. α‐Glycosidase inhibitor compounds can be utilized as a novel group of
antidiabetic drugs. By competitively decreasing glycosidase activity, these
inhibitor molecules help to hamper the fast breakdown of sugar molecules and
thereby control the blood sugar level.
